Gain Therapeutics Stock (NASDAQ: GANX) stock price, news, charts, stock research, profile.
Open | - |
Close | - |
Volume / Avg. | 0 / 161.218K |
Day Range | - - - |
52 Wk Range | 2.000 - 5.650 |
Market Cap | $48.497M |
P/E Ratio | - |
Dividend Yield | - |
Exchange | NASDAQ |
RSI | 32 |
Short Interest | 0.91% |
Days to Cover | 1.02 |
Name |
---|
Revenue Change |
Gross Change |
EBITDA Change |
EBIT Change |
Earnings Change |
You can purchase shares of Gain Therapeutics (NASDAQ: GANX) through any online brokerage.
Other companies in Gain Therapeutics’s space includes: NKGen Biotech (NASDAQ:NKGN), Kezar Life Sciences (NASDAQ:KZR), Intensity Therapeutics (NASDAQ:INTS), Eagle Pharmaceuticals (NASDAQ:EGRX) and Immuneering (NASDAQ:IMRX).
The latest price target for Gain Therapeutics (NASDAQ: GANX) was reported by HC Wainwright & Co. on Thursday, April 25, 2024. The analyst firm set a price target for 9.00 expecting GANX to rise to within 12 months (a possible 201.00% upside). 14 analyst firms have reported ratings in the last year.
The stock price for Gain Therapeutics (NASDAQ: GANX) is $2.99 last updated April 25, 2024 at 9:19 AM EDT.
There are no upcoming dividends for Gain Therapeutics.
Gain Therapeutics’s Q1 earnings are confirmed for Friday, May 10, 2024.
There is no upcoming split for Gain Therapeutics.
Gain Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.